Summary.-Antibodies to bleomycin were raised by immunization of sheep and rabbits with bleomycin-albumin conjugates. The combination of a high-titre, highavidity sheep antiserum and iodinated bleomycin produced a radioimmunoassay sensitive to 8 ng of bleomycin per ml of plasma or urine. Untreated specimens (100 tul) of plasma or urine could be added directly to the assay tubes. The antiserum was specific for bleomycin and showed no cross-reaction with other anticancer agents used in combination chemotherapy. Over a concentration range of 20-100 ng/ml, recovery of bleomycin from plasma was 110% and from urine, 93%. Repeated assay of plasma samples showed a decrease in bleomycin levels unless the samples were kept at 4°C or below. Assay of bleomycin levels in plasma and urine from patients under treatment with bleomycin showed similarities with results reported using a microbiological assay. The radioimmunoassay offers a more reliable, rapid and sensitive method for the measurement of bleomycin. BLEOMYCIN (BM) is a group of antineoplastic antibiotics, produced by the fungus Streptomyces verticillus, the members of which are partially polypeptide in structure (Umezawa, 1973) . Although there are many reported components of varying activity (Cohen and I, 1976) , the therapeutic preparation consists mainly of bleomycin A2 and B2. These have proved particularly useful in the treatment of squamous-cell carcinoma, sarcoma and malignant lymphoma. The minimal suppressive effect of BM on human bone marrow is an important attribute, but the appearance of pulmonary toxicity is a side effect which is unpredictable at low dose and increases rapidly with high doses. Continuous monitoring of the blood levels of BM during therapy may, therefore, be of benefit in restricting toxic side effects whilst maintaining maximal antineoplastic activity.
BLEOMYCIN (BM) is a group of antineoplastic antibiotics, produced by the fungus Streptomyces verticillus, the members of which are partially polypeptide in structure (Umezawa, 1973) . Although there are many reported components of varying activity (Cohen and I, 1976) , the therapeutic preparation consists mainly of bleomycin A2 and B2. These have proved particularly useful in the treatment of squamous-cell carcinoma, sarcoma and malignant lymphoma. The minimal suppressive effect of BM on human bone marrow is an important attribute, but the appearance of pulmonary toxicity is a side effect which is unpredictable at low dose and increases rapidly with high doses. Continuous monitoring of the blood levels of BM during therapy may, therefore, be of benefit in restricting toxic side effects whilst maintaining maximal antineoplastic activity.
The principal method for BM measurement has been assessment of the inhibition of bacterial growth on culture medium by the samples under analysis (Ohnuma et al., 1974) . Whilst this technique possesses sufficient sensitivity for the estimation of blood and urine BM levels, the procedure is much more time-consuming than radioimmunoassay (RIA).
The comparatively high molecular weight of BM and its peptide-like structure confer the property of immunogenicity on protein conjugates of the drug, which permits rapid production of anti-BM sera. In addition, the drug is susceptible to simple iodination. With these reagents a rapid RIA procedure can be developed (Broughton and Strong, 1976) .
MATERIALS AND METHODS
Preparation of immunogen.-Bleomycin sulphate (donated bv Lundbeck Ltd.) was conjugated to bovine serum albumin (BSA) by a carbodiimide condensation reaction. 90 mg of BM (Lot UIIAS) and 100 mg of BSA were dissolved in 5 ml of distilled water. 70 mg of ethyl-(dimethyl-amino-propyl)-carbodiimide was then added, and the solution stirred overnight at room temperature. Unconjugated BM was removed by dialysis against several changes of 500-ml volumes of distilled water. The conjugate solution was lyophilized under vacuum. The amount of BM conjugated was determined by UV analysis of the amount recovered in the dialysates, and its subtraction from the quantity used originally. By this method it was calculated that the conjugate contained 13 mol BM per mol BSA.
Immunization.-The BM-BSA conjugate was injected into 2 sheep. 15 mg of conjugate and 3 mg BCG vaccine were dissolved in 7-5 sterile water and emulsified with 7*5 Marcol 52/Arlacel A (9:1) and 7-5 ml Tween 80. 041 ml aliquots of emulsion were injected intradermally into 40 sites on the back of one sheep (HP/S/65). 6 x 1-ml aliquots were injected s.c. into the back and 6 x 0-5-ml aliquots i.m. into the legs of the second sheep (HP/S/66). Blood was collected at regular intervals from the jugular vein. The serum was separated and stored, after the addition of sodium azide to a final concentration of 0.1%, in a refrigerator at 40C. High-titre antisera were lyophilized under vacuum in aliquots of 1: 4 dilution with 0-04M phosphate buffer, pH 7-4.
Production of iodinated bleomycin.-The procedure is essentially that described by Broughton and Strong (1976) . Into a small glass vial were placed 10 ,ul of a 500-jug/ml solution of BM in 01M borate buffer, pH 8-6 and 10 ,ul of [1251]Nal (100 mCi/ml). 10 ,ul of chloramine T solution (5 mg/ml in borate buffer) were then added and the mixture left for 1 min at room temperature before the addition of 10 ,ul of sodium metabisulphite solution (12 mg/nl in borate buffer).
The reaction mixture was transferred to a (12 x 1.25) cm Sephadex G-10 column and eluted with 01M phosphate buffer, pH 7.4, containing 0a1% gelatin. 1-ml fractions were collected and 10-,ul aliquots of each fraction were monitored for radioactivity. Fractions eluted at the column void volume, and containing the highest level of radioactivity, were combined and stored at 4°C until used. The immunoreactivity of the iodinated material was stable for at least 4 months. Assay procedure.-Standard radioimmunoassay techniques were employed (Teale et al., 1975) . The assay protocol used is shown in Table I . The [1251]BM was diluted immediately before use to 1000 ct/s/ml with assay buffer (01M phosphate, pH 7 4, containing 0.1% gelatin). Antiserum was used at the dilution (titre) at which 50% of the label was bound to antibody. Stock stand-56 ard solutions of BM containing 1 ,tg/ml were stored at -200C and diluted before use.
Dextran-coated charcoal (2.5%) was used in the separation stage, as previously described (Teale et al., 1975) . Unextracted normal human plasma or urine could be added to the assay in volumes up to 100 ,u without significantly affecting the binding of the label to antiserum or its sensitive displacement by drug standards.
Animal experiments.-Two Half-lop rabbits (2.5-3.5 kg) were given i.v. doses of BM by iinjection into the lateral ear veins. On the first occasion, a dose of 0 5 mg/kg in saline was given, and after several weeks this was followed by a second dose of 1-0 mg/kg. Blood was collected at frequent intervals from the contralateral ear vein for up to 3 h. Plasma was analysed for BM content using the RIA.
RESULTS
Both sheep immunized with BM-BSA conjugate produced antisera of relatively high titre. HP/S/65 reached a peak titre (1/2000 final dilution) at 22 weeks after immunization. HP/S/66 produced an antibody titre of 1/12000 also at 22 weeks after priming.
Standard curves were constructed using the same BM preparation as standard that had been used both for immunogen preparation and iodination. An example of a standard curve produced using the protocol in Table I is shown in Fig. 1 . By constructing a Scatchard plot from this standard curve, the avidity constant of the assay antiserum (HP/S/66-1C) was calculated as 1 x 109 1/mol. Assay sensitivity for BM in plasma was calculated (Albano and Ekins, 1970) as 8 ng/ml. Table II lists the compounds tested for antibody cross-reactivity and found not to inhibit label from binding to antibody, even when present in amounts up to 1 , per tube (equivalent to 20 ,ug/ml).
BM was added to normal plasma and urine at several known concentrations and the specimens assayed on several occasions. Mean recoveries in the concentration range 20-100 ng/ml were 110 i 4% in plasma and 93 ± 11% in urine. After 8 assays of the plasma pool, interassay and within-assay variations were both 12%. After 5 assays of the urine pool, inter-assay variation was 20% and within-assay variation 16%.
The assay results on plasma samples of the BM administered was recovered in the urine during the first 7-5 h.
DISCUSSION
It is apparent from this study and an earlier report by Broughton and Strong (1976) that BM-protein conjugates are highly immunogenic and capable of eliciting high-titre high-avidity antisera in immunized animals. In addition to stimulating the production of antibodies in sheep we have also raised high-titre antisera in rabbits, but these have not been considered in the present paper.
Since the therapeutic preparation of BM is a mixture of A1, A2 and B2 components, antisera were tested for reactivity with the individual pure compounds. HP/S/66-1C exhibited similar avidities for the A2 and B2 components which comprise 99% of the therapeutic mixture. For this reason this antiserum was used in the assay of specimens. Whether the antiserum also cross-reacts with BM metabolites and/or immunoreactive fragments remains speculative, but the similarity in plasma disappearance and urinary excretion rates when measured by RIA (Fig. 4) or bioassay (Ohnuma et al., 1974) suggest that the RIA measures total antibiotic activity, which is probably, though not necessarily, equivalent to its antitumour activity. The antiserum (HP/S/66-1C) chosen for use in the assay showed no crossreaction with several therapeutic drugs in common use, nor with other antineoplastic agents often used in combination with BM. The assay specificity for BM, therefore, permits drug measurements to be performed on untreated plasma and urine samples.
The RIA of BM in plasma showed good recovery values when the drug was added to normal plasma and urine. Variation in recovery occurred when specimens were stored at 4°C for prolonged periods or at room temperature for short periods. It has been reported (Ohnuma et al., 1974 ) that inactivation of BM by plasma can occur during incubation at 37°C, although this treatment had no effect on urinary levels. The sensitivity of the RIA is 8 ng/ml, compared with the reported range of 100-250 ng/ml for bacteriological assay. Although the latter sensitivity range is adequate for the measurement of plasma levels shortly after the usual i.v. dose of BM, the RIA offers a much simplified, more rapid and sensitive procedure. Furthermore, tissue drug levels should be detectable and measurable by the RIA method, but so far we have no information on this point.
The application of RIA to the measurement of BM levels during therapy should provide a rapid method for continuous control of patient dosage and should be especially useful when applied to combination therapy in which BM is administered together with other cytotoxic drugs such as methotrexate (Aherne, Piall and Marks, in preparation) and vincristine (Teale, Clough and Marks, 1977) for which RIAs have been produced.
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